Critically, FSTL1 is tightly linked to sorafenib resistance, and combining an anti-FSTL1 antibody with sorafenib prolonged mice survival with reduced tumor stemness, illustrating the potential clinical benefits of FSTL1 targeting, either as a single agent or in combination with sorafenib.83 Here, FSTL1 is linked to neoplasm.